CA2296319A1 - Vecteurs lentiviraux - Google Patents

Vecteurs lentiviraux Download PDF

Info

Publication number
CA2296319A1
CA2296319A1 CA002296319A CA2296319A CA2296319A1 CA 2296319 A1 CA2296319 A1 CA 2296319A1 CA 002296319 A CA002296319 A CA 002296319A CA 2296319 A CA2296319 A CA 2296319A CA 2296319 A1 CA2296319 A1 CA 2296319A1
Authority
CA
Canada
Prior art keywords
promoter
cells
gene
expression
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002296319A
Other languages
English (en)
Inventor
Shin-Tai Chen
Mehdi Gasmi
Jiing Kuan Yee
Douglas J. Jolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2296319A1 publication Critical patent/CA2296319A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des vecteurs lentiviraux comprenant une longue répétition terminale (LTR) lentivirale 5', un site de fixation d'ARNt, un signal d'encapsidation, un promoteur fixé de manière fonctionnelle à un ou à plusieurs gènes d'intérêt, une origine de la synthèse du second brin d'ADN et une LTR lentivirale 3', le vecteur lentiviral contenant un élément de transport nucléaire qui n'est pas RRE (site de liaison de la protéine Rex). L'invention concerne également des cassettes d'expression et des lignées de cellules d'encapsidation permettant de produire des particules de vecteurs lentiviraux.
CA002296319A 1997-07-18 1998-07-20 Vecteurs lentiviraux Abandoned CA2296319A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5306697P 1997-07-18 1997-07-18
US60/053,066 1997-07-18
PCT/US1998/014996 WO1999004026A2 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Publications (1)

Publication Number Publication Date
CA2296319A1 true CA2296319A1 (fr) 1999-01-28

Family

ID=21981716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296319A Abandoned CA2296319A1 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Country Status (5)

Country Link
EP (1) EP1003894A2 (fr)
JP (1) JP2001510053A (fr)
AU (1) AU8576298A (fr)
CA (1) CA2296319A1 (fr)
WO (1) WO1999004026A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO2000000600A2 (fr) * 1997-09-22 2000-01-06 Chang Lung Ji Vecteurs lentiviraux
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2002508338A (ja) * 1997-12-12 2002-03-19 ナルディニ，ルイジ レンチウィルスベクターの治療使用
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (fr) * 1998-01-16 1999-07-22 Chiron Corporation Vecteurs de therapie genique du virus de l'immunodeficience feline
WO2000006760A1 (fr) * 1998-07-29 2000-02-10 The Government Of The United States Of America, R Epresented By The Secretary, Department Of Health And Human Services Utilisation d'elements de transport constitutifs pour le control de la gamme d'hote
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
CA2371216A1 (fr) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotype de vecteur retroviral destine a la therapie genique du cancer
EP1849873B1 (fr) * 1999-04-29 2011-10-12 Gbp Ip, Llc Procédé et supports de production de vecteurs de lentivirus recombinant sécurisé à fort dosage
US6730297B1 (en) * 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
ATE342999T1 (de) * 1999-06-09 2006-11-15 Univ Cambridge Tech Auf siv basierende verpackungsdefiziente vektoren
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU2001278430A1 (en) * 2000-05-22 2001-12-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Systemic and cardiovascular transduction with lentiviral vectors
WO2001092506A1 (fr) * 2000-05-30 2001-12-06 University Of Rochester Systemes de vecteurs lentiviraux derives de virus d'immunodeficience simienne (siv)
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en) 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
RU2362584C2 (ru) 2003-03-07 2009-07-27 Робартс Рисерч Инститьют Применение вируса миксомы для терапевтического лечения рака и хронической вирусной инфекции
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2388315B1 (fr) 2005-03-07 2014-05-21 The University of Western Ontario Utilisation d'un virus du myxome n'exprimant pas de protéine M135R functionelle pour utilisation thérapeutique
EP3031923A1 (fr) * 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
MA41382A (fr) * 2015-03-20 2017-11-28 Univ Temple Édition génique basée sur le système crispr/endonucléase à induction par tat
JP2018510160A (ja) * 2015-03-20 2018-04-12 ブルーバード バイオ， インコーポレイテッド ベクター製剤
WO2019009979A1 (fr) 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles
WO2019219049A1 (fr) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 Protéine de fusion du fviii améliorée et utilisation associée
WO2020059848A1 (fr) * 2018-09-20 2020-03-26 国立大学法人東京医科歯科大学 Procédé d'amélioration de la production de vecteurs de lentivirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1123497A (en) * 1995-11-28 1997-06-19 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome

Also Published As

Publication number Publication date
WO1999004026A3 (fr) 1999-04-08
AU8576298A (en) 1999-02-10
EP1003894A2 (fr) 2000-05-31
JP2001510053A (ja) 2001-07-31
WO1999004026A2 (fr) 1999-01-28

Similar Documents

Publication Publication Date Title
CA2296319A1 (fr) Vecteurs lentiviraux
EP1045921A2 (fr) Vecteurs de therapie genique du virus de l'immunodeficience feline
CA2523216C (fr) Vecteurs d'alphavirus recombinant
EP0702084B1 (fr) Rétrovirus recombinants
WO1996037626A1 (fr) Integration de vecteurs de recombinaison dans une position specifique du genome d'un eucaryote, assuree par une proteine chimere du type integrase
WO1998000541A9 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
EP0951544A2 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
EP0800403A2 (fr) Administration atraumatique de vehicules d'apport de genes
WO1996020732A9 (fr) Administration atraumatique de vehicules d'apport de genes
US20030003565A1 (en) Functional lentiviral vector from an MLV-based backbone
US20050214258A1 (en) Vectors for delivering viral and oncogenic inhibitors
JPH11507244A (ja) Ｓｒｖ−３エンベロープ糖タンパク質配列で偽型化したレトロウイルスベクター
WO2002002789A2 (fr) Compositions et procedes permettant de fabriquer des virions de recombinaison
EP0796331A2 (fr) Production et administration de retrovirus recombines a titre eleve
JPH11504802A (ja) 組換えアルファウイルスベクター
US6953687B1 (en) Vectors for delivering viral and oncogenic inhibitors
US20060121011A1 (en) Combination gene delivery vehicles
AU774551B2 (en) Vectors for delivering viral and oncogenic inhibitors
AU689799B2 (en) Recombinant retroviruses
JPH10511951A (ja) 高力価組換えレトロウイルスの産生および投与

Legal Events

Date Code Title Description
FZDE Discontinued